CohBar, Inc.

NASDAQ:CWBR

$0.88005 USD

$0.12 (15.76%)

Volume
590
Average Volume
5.52K
Market Capitalization
$2.56M
P/E Ratio
-0.21
Dividend Yield
0.00%
Price Target
$
Year High
$6.90
Year Low
$0.58
Payout Ratio
$0.00
Current Ratio
$4.16

Industry, Sector & symbol

Stock Exchange NASDAQ Capital Market
CEO Dr. Pinchas Cohen Dean, M.D.
Industry Biotechnology
Sector Healthcare
Current Symbol CWBR
CUSIP 19249J109
CIK 0001522602
Web https://www.cohbar.com
Phone 650 446 7888
Currency USD
Employees 9
Country US

Liquidity

Debt-to-Equity Ratio 0.00
Payout Ratio 0.00
Current Ratio 4.16
Quick Ratio 4.12
Cash Ratio 2.06

Sales & Book Value

Annual Sales $-
Price / Sales 0.00
Cash Flow -2.73
Price / Cash Flow -0.32
Price / Book 0.27

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Neutral
Rating Score(0-5) 3
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-4.12
Trailing P/E Ratio -0.21
PEG Ratio -0.01
P/E Growth -0.01
Net Income $-11.96M
Net Margin 0.00%
Pretax Margin 0.00%
Return on Equity -86.52%
Return on Assets -98.73%

Financials Score

AltmanZ Score -13.66
Piotroski Score 1.00
Working Capital 9.47M
Total Assets 12.51M
Ebit -13.03M
Market Cap 2.21M
Total Liabilities 3M

Poll Results

About CohBar, Inc. (NASDAQ:CWBR) Stock

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was inc ... orporated in 2007 and is headquartered in Menlo Park, California.

Why Is CohBar (CWBR) Stock Up 130% Today?

2023-05-23 11:44:07

CohBar (NASDAQ: CWBR ) stock is soaring higher on Tuesday after the company announced a planned merger with Morphogenesis . CohBar and Morphogenesis are planning for an all-stock merger that will see the two combine to create a new company named “TuHURA Biosciences, Inc.” This company will continue to trade its shares on The Nasdaq Capital Market.

CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022

2022-10-26 09:00:00

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

Cohbar Inc. (CWBR) Upgraded to Strong Buy: What Does It Mean for the Stock?

2022-10-21 13:33:21

Cohbar Inc. (CWBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

7 Nasdaq Stocks to Sell Before They Die

2022-09-26 18:21:01

As is typical of a bear market, the Nasdaq has led the other major indices lower over the past year. The tech-heavy index is down 28% over the past 12 months compared with a 17% decline in the S&P 500.

CohBar (CWBR) Stock: 1-For-30 Reverse Split Goes Into Effect

2022-09-23 08:35:56

A 1-for-30 reverse split of CohBar (CWBR) stock has gone into effect today. These are the details.

Frequently Asked Questions

What is the current CohBar, Inc. (CWBR) stock price?

CohBar, Inc.(NASDAQ:CWBR) stock price is $0.88005 in the last trading session. During the trading session, CWBR stock reached the peak price of $6.9 while $0.58 was the lowest point it dropped to. The percentage change in CWBR stock occurred in the recent session was 15.76% while the dollar amount for the price change in CWBR stock was $0.12.

CWBR's industry and sector of operation?

The NASDAQ listed CWBR is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of CWBR?

Dr. John M. Amatruda M.D., Ph.D. | Co-Founder
Dr. Nir Yacov Barzilai M.D. | Founder & Member of Scientific Advisory Board
Dr. Pinchas Cohen Dean, M.D. | Founder & Member of Scientific Advisory Board
Ms. Jordyn Tarazi | Director of Investor Relations
|

How many employees does CWBR have?

Number of CWBR employees currently stands at 9. CWBR operates from 1455 Adams Drive, Menlo Park, CA 94025, US.

Link for CWBR official website?

Official Website of CWBR is: https://www.cohbar.com

How do I contact CWBR?

CWBR could be contacted at phone #650 446 7888 and can also be accessed through its website. CWBR operates from 1455 Adams Drive, Menlo Park, CA 94025, US.

How many shares of CWBR are traded daily?

The average number of CWBR shares traded daily for last 3 months was 5.52K.

What is the market cap of CWBR currently?

The market value of CWBR currently stands at $2.56M with its latest stock price at $0.88005